A mid-size diagnostic laboratory was doing $30 million in revenue and barely breaking even. When COVID-19 hit, the leadership team made a bet most labs weren't positioned to make: pivot the entire operation to high-throughput molecular testing. The science was sound. The question was whether a company of that size could scale fast enough to compete for state-level contracts against labs with ten times its resources.

Without the pivot, the company faced the same slow decline as dozens of regional labs that couldn't find their footing in a market that changed overnight. Molecular testing demand was surging, but the window to capture state contracts was narrow. Miss it, and the opportunity would go to larger, better-capitalized competitors.

One of Acumen's principals, serving as CFO and COO, was central to both the strategic decision and the execution that followed. The company scaled from a small team to over 800 employees. It won large, multi-state testing contracts. When a global reagent shortage shut down competitors who hadn't locked in supply, the company's vendor relationships and disciplined cash management kept operations running at full capacity. That supply chain advantage became a competitive moat during the months when testing demand peaked, and most labs couldn't deliver.

Revenue grew from $30 million to approximately $1.5 billion. The company conducted high-throughput testing across multiple states, serving millions of patients during the most acute phase of the public health crisis.

A leader in building this business now advises at Acumen. That's the difference between a firm that gives recommendations and a firm that has operated through the hardest conditions in modern healthcare.